Related Experiment Video
Updated: Jul 24, 2025

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
Protopanaxadiol ameliorates palmitate-induced lipotoxicity and pancreatic β-cell dysfunction in INS-1 cells
Dahae Lee1, Sungyoul Choi1, Ki Sung Kang1
1College of Korean Medicine, Gachon University, Seongnam, Republic of Korea.
Background:
Free fatty acid-induced lipotoxicity is considered to play an important role in pancreatic β-cell dysfunction. The effect of ginsenosides on palmitic acid-induced pancreatic beta-cells cell death and failure of glucose-stimulated secretion of insulin (GSIS) was evaluated in this study.
Methods:
Enzyme-linked immunosorbent assay kit for a rat insulin was used to quantify glucose-stimulated insulin secretion. Protein expression was examined by western blotting analysis. Nuclear condensation was measured by staining with Hoechst 33342 stain. Apoptotic cell death was assessed by staining with Annexin V. Oil Red O staining was used to measure lipid accumulation.
Results:
We screened ginsenosides to prevent palmitic acid-induced cell death and impairment of GSIS in INS-1 pancreatic β-cells and identified protopanaxadiol (PPD) as a potential therapeutic agent. The protection effect of PPD was likely due to a reduction in apoptosis and lipid accumulation. PPD attenuated the palmitic acid-induced increase in the levels of B-cell lymphoma-2-associated X/B-cell lymphoma 2, poly (ADP-ribose) polymerase and cleaved caspase-3. Moreover, PPD prevented palmitic acid-induced impairment of insulin secretion, which was accompanied by an increase in the activation of phosphatidylinositol 3-kinase, peroxisome proliferator-activated receptor γ, insulin receptor substrate-2, serine-threonine kinase, and pancreatic and duodenal homeobox-1.
Conclusion:
Our results suggest that the protective effect of PPD on lipotoxicity and lipid accumulation induced by palmitic acid in pancreatic β-cells.
Insights
Protopanaxadiol (PPD) protects pancreatic beta cells from palmitic acid-induced lipotoxicity. PPD reduces cell death and improves insulin secretion by decreasing lipid accumulation and apoptosis.
Area of Science:
- Endocrinology
- Cell Biology
- Pharmacology
Background:
- Free fatty acid-induced lipotoxicity contributes to pancreatic beta-cell dysfunction.
- Palmitic acid exposure impairs beta-cell function and insulin secretion.
Purpose of the Study:
- To evaluate the effect of ginsenosides on palmitic acid-induced pancreatic beta-cell death and glucose-stimulated insulin secretion (GSIS).
- To identify potential therapeutic agents from ginsenosides for treating lipotoxicity.
Main Methods:
- Screening of ginsenosides for protective effects on INS-1 pancreatic beta-cells.
- Quantification of GSIS using an insulin ELISA kit.
- Assessment of apoptosis, lipid accumulation, and protein expression via staining and western blotting.
Main Results:
- Protopanaxadiol (PPD) was identified as a potential therapeutic agent, preventing palmitic acid-induced cell death and GSIS impairment.
- PPD reduced apoptosis and lipid accumulation in beta-cells.
- PPD modulated apoptosis-related proteins (Bcl-2, PARP, caspase-3) and signaling pathways (PI3K, PPARγ, IRS-2, Akt, PDX-1).
Conclusions:
- PPD exhibits a protective effect against palmitic acid-induced lipotoxicity and lipid accumulation in pancreatic beta-cells.
- PPD demonstrates therapeutic potential for managing beta-cell dysfunction associated with lipotoxicity.
More Related Videos
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
Related Concept Videos
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin Secretory Vesicles